New results from the Phase III MATTERHORN trial show AstraZeneca’s Imfinzi combination reduced the risk of death by 22% versus chemotherapy alone, marking a major advance for patients with resectable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback